This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by KLIBANSKI, A. Articles by BIKKAL, H. Search for Related Content PubMed PubMed Citation Articles by KLIBANSKI, A. Articles by BIKKAL, H.

Gonadotropin and -Subunit Responses to Chronic Gonadotropin-Releasing Hormone Analog Administration in Patients With Glycoprotein Hormone- Secreting Pituitary Tumors^*

Departments of Medicine and Neurosurgery and the Clinical Research Center, Massachusetts General Hospital, Boston Massachusetts 02114
The Salk Institute, LaJolla California 92037

Address requests for reprints to: Dr. Anne Klibanski, Thyroid Unit, Massachusetts General Hospital, ACC-6, Boston Massachusetts 02114.

Pituitary tumors secreting intact glycoprotein hormones (LH, FSH, and TSH) and/or -subunit are being increasingly recognized. Because chronic administration of GnRH analogs decreases gonadotropin secretion in normal subjects, we investigated gonadotropin and -subunit responses to chronic GnRH analog administration in five men with glycoprotein hormone-secreting pituitary tumors. Two patients (patients A and B) received the GnRH agonist analog (D-Trp⁶-Pro⁹-NEt- LHRH) for 4 weeks as a daily sc dose (8 µg/kg·day). In both, secretion of LH and/or -subunit increased markedly. Subsequently, three patients received a higher analog dose (32 µg/kg·day) for a longer duration (8 weeks). One patient with a LHand FSH-secreting tumor (patient C) had a highly significant (P < 0.001) fall in serum LH and FSH concentrations; however, -subunit secretion increased. During a subsequent study, when this patient received a lower dose (8 µg/kg·day) for 8 weeks, gonadotropin suppression also occurred. In two additional patients who received this dose (32 µg/kg·day), it had a persistentagonist effect on FSHβ (patient D) and -subunit secretion (patient E). A marked increase in a-subunit secretion occurred in all five patients, regardless of whether basal serum -subunit concentrations were elevated. These patients received the GnRH analog at doses 2–8 times greater than those that suppress gonadotropin secretion in normal men. Serum LH and FSH concentrations decreased in onlyone patient with a gonadotropin- secreting adenoma. The serum LH and FSH responses to acute GnRH stimulation did not predict the gonadotropin responses to chronic GnRH analog administration. Thus, gonadotropin and -subunit production by most pituitary adenomas is augmentedduring chronic GnRH analog administration, consistent with defective GnRH desensitization in the adenomatous tissue. Despite the heterogeneous gonadotropin responses to the GnRH analog in these patients, serum -subunit levels increased in all patients, indicating dissociation in the secretion of intact gonadotropins and -subunit.

^* Presented in part at the 68th Annual Meeting of The Endocrine Society Meeting, 1986. This work was supported in part by Grants HD-21204 and RR-01066 from the NIH.

Received May 2, 1988.

This article has been cited by other articles:

				A. Colao, C. Di Somma, R. Pivonello, A. Faggiano, G. Lombardi, and S. Savastano Medical therapy for clinically non-functioning pituitary adenomas Endocr. Relat. Cancer, December 1, 2008; 15(4): 905 - 915. [Abstract] [Full Text] [PDF]

				W. van Biljon, S. Wykes, S. Scherer, S.A. Krawetz, and J. Hapgood Type II Gonadotropin-Releasing Hormone Receptor Transcripts in Human Sperm Biol Reprod, December 1, 2002; 67(6): 1741 - 1749. [Abstract] [Full Text] [PDF]

				I. Cedrin-Durnerin, J.-M. Bidart, P. Robert, J.-P. Wolf, M. Uzan, and J.-N. Hugues Consequences on gonadotrophin secretion of an early discontinuation of gonadotrophin-releasing hormone agonist administration in short-term protocol for in-vitro fertilization Hum. Reprod., May 1, 2000; 15(5): 1009 - 1014. [Abstract] [Full Text] [PDF]

				H. B. Lavoie, K. A. Martin, A. E. Taylor, W. F. Crowley, and J. E. Hall Exaggerated Free {alpha}-Subunit Levels during Pulsatile Gonadotropin-Releasing Hormone Replacement in Women with Idiopathic Hypogonadotropic Hypogonadism J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 241 - 247. [Abstract] [Full Text]